Market Cap 84.57M
Revenue (ttm) 154.90M
Net Income (ttm) -20.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13.04%
Debt to Equity Ratio 11.85
Volume 5,002,400
Avg Vol 2,846,780
Day's Range N/A - N/A
Shares Out 189.28M
Stochastic %K 11%
Beta 1.58
Analysts Sell
Price Target $3.67

Company Profile

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed na...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 251 4400
Address:
100 Regency Forest Drive, Suite 300, Cary, United States
SpaceForceOne
SpaceForceOne Jun. 5 at 3:59 PM
$HRTX Brad- Neither is going to happen, if even for years to come. While steps to avoid such claims could / will be detrimental to current investors, I am confident $HRTX is NOT going to be delisted or bankrupt. The competitive generic Civ product wouldn’t be mass produced at the earliest until late sometime 2028 in perfect conditions. $HRTX stated they have cash on hand for short term. This stock will fluctuate I bet a few times between now and PFS. Tell everyone who has blocked me, I have proclaimed. lol.
2 · Reply
Braddog
Braddog Jun. 5 at 3:40 PM
$HRTX The shorts are going to force Heron into a bad situation! Someone doesn’t want Zyn in the market I wonder who that could be? 😡
0 · Reply
Ethan11111
Ethan11111 Jun. 5 at 3:26 PM
$HRTX the stock price is ridiculous, almost impossible...
1 · Reply
Braddog
Braddog Jun. 5 at 3:15 PM
$HRTX We could see the price in $0.20s.
0 · Reply
Braddog
Braddog Jun. 5 at 3:11 PM
$HRTX The shorts will not let up until Heron is de-listed or BK! The only way out of this is a structural change in the Company! Pray I get some of my $$$ back!
0 · Reply
BullMaven
BullMaven Jun. 5 at 2:30 PM
$HRTX keep adding
1 · Reply
Braddog
Braddog Jun. 5 at 1:52 PM
$HRTX Heron saying that Q1 sales were bad because of the weather is such a joke! I believe BQ once blamed poor sales on the weather! COLLARD HAS FAILED! His primary job is bring shareholder value! 😡 Where are the Blockbuster sales! 😡
1 · Reply
Braddog
Braddog Jun. 5 at 1:32 PM
$HRTX After this horrible week if your a long investor, HERON has several concerns 1st The loss against Azurity is worse than people think Its is setting us back years AGAIN if you are a long investor 2nd If Heron needs money to keep operation going, long investors most likely will be more Fucked! Not a lot of good outcomes 3rd Will Heron have to Reverse split? No way this goes above $1 without structural change or winning the Appeal! 4th. The shorts aren’t going anywhere! They finally got Heron pinned down and are going in for the kill! Seriously I think selling this for whatever is our only way out I can’t imagine Rubic and Velan want to hang around here for 5 more years Heron is cursed. Nothing goes its way Nothing. Collard hasn’t done his job! I’m still want to know the truth about Azurity’s argument because COLLARD AND TEAM said it was the SAME JUDGE with the SAME ARGUEMENT! Well it WASN’T! WISH I NEVER HEARD OF HERON!
0 · Reply
Alon_R
Alon_R Jun. 5 at 10:05 AM
$HRTX If Q2 once again reaffirms the $173–183M rev. guidance & $10–20M EBITDA, I believe SP could move well above $1 in a short period, possibly even $2+ range this year. The reasoning is straightforward-> First & foremost, the company is financially sound. That's the foundation. Second, we're seeing rapid uptake of two approved franchises. According to guidance, they are expected to grow ~80% YoY on average! Anyone who understands what strong adoption & rapid growth of two approved franchises can lead to knows where this is heading. More importantly, this growth validates the company's financial strength going forward. If both franchises generate ~$90M in 2026 after growing ~80%, the likely paths are either continued rapid expansion, becoming first-line treatments, or a moderation to ~40% growth. Either way,the company becomes financially solid & continue growing from there. And yes, in that scenario, it becomes an attractive buyout candidate, potentially $500–700M range.
2 · Reply
Suhada_95
Suhada_95 Jun. 5 at 4:31 AM
$HRTX My short selling friends, I hope you are still strong enough to lower the price of this stock to 0.35, because my average price is only at 0.79$
1 · Reply
Latest News on HRTX
Heron Therapeutics downgraded to Hold from Buy at Needham

2026-06-02T20:07:25.000Z - 2 days ago

Heron Therapeutics downgraded to Hold from Buy at Needham


Heron Therapeutics reports Q1 EPS (4c), consensus (2c)

2026-05-11T16:41:43.000Z - 25 days ago

Heron Therapeutics reports Q1 EPS (4c), consensus (2c)


Heron Therapeutics Earnings Call Transcript: Q1 2026

May 11, 2026, 8:30 AM EDT - 25 days ago

Heron Therapeutics Earnings Call Transcript: Q1 2026


Heron Therapeutics Earnings release: Q1 2026

May 11, 2026, 8:30 AM EDT - 25 days ago

Heron Therapeutics Earnings release: Q1 2026


Heron Therapeutics Quarterly report: Q1 2026

May 11, 2026, 8:30 AM EDT - 25 days ago

Heron Therapeutics Quarterly report: Q1 2026


Heron Therapeutics Slides: Q1 2026

May 11, 2026, 8:30 AM EDT - 25 days ago

Heron Therapeutics Slides: Q1 2026


Heron Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Heron Therapeutics Proxy statement: Proxy filing


Heron Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Heron Therapeutics Proxy statement: Proxy filing


Heron Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 6 weeks ago

Heron Therapeutics Proxy statement: Proxy filing


Heron Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 3 months ago

Heron Therapeutics Earnings Call Transcript: Q4 2025


Heron Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 3 months ago

Heron Therapeutics Annual report: Q4 2025


Heron Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 3 months ago

Heron Therapeutics Earnings release: Q4 2025


Heron Therapeutics Slides: Q4 2025

Feb 26, 2026, 8:30 AM EST - 3 months ago

Heron Therapeutics Slides: Q4 2025


Heron Therapeutics reports Q4 EPS (2c) vs 2c last year

2026-02-26T13:22:25.000Z - 3 months ago

Heron Therapeutics reports Q4 EPS (2c) vs 2c last year


Heron Therapeutics sees FY26 revenue $173M-$183M

2026-02-26T13:22:12.000Z - 3 months ago

Heron Therapeutics sees FY26 revenue $173M-$183M


Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M

2026-01-09T14:35:13.000Z - 5 months ago

Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M


Heron Therapeutics Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 7 months ago

Heron Therapeutics Earnings Call Transcript: Q3 2025


Heron Therapeutics Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 7 months ago

Heron Therapeutics Quarterly report: Q3 2025


Heron Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 7 months ago

Heron Therapeutics Earnings release: Q3 2025


Heron Therapeutics Slides: Q3 2025

Nov 4, 2025, 8:30 AM EST - 7 months ago

Heron Therapeutics Slides: Q3 2025


Heron Therapeutics reports Q3 EPS (10c), consensus (1c)

2025-11-04T13:05:21.000Z - 7 months ago

Heron Therapeutics reports Q3 EPS (10c), consensus (1c)


Heron Therapeutics Proxy statement: Proxy Filing

Sep 19, 2025, 8:00 AM EDT - 9 months ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics files $125M mixed securities shelf

2025-09-09T21:15:15.000Z - 9 months ago

Heron Therapeutics files $125M mixed securities shelf


Heron Therapeutics Registration statement: Registration Filing

Sep 9, 2025, 8:00 AM EDT - 9 months ago

Heron Therapeutics Registration statement: Registration Filing


Heron Therapeutics Registration statement: Registration Filing

Sep 9, 2025, 8:00 AM EDT - 9 months ago

Heron Therapeutics Registration statement: Registration Filing


Heron Therapeutics Proxy statement: Proxy Filing

Sep 9, 2025, 8:00 AM EDT - 9 months ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics adopts tax benefits preservation plan

2025-08-15T11:50:16.000Z - 10 months ago

Heron Therapeutics adopts tax benefits preservation plan


Heron Therapeutics Earnings Call Transcript: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 10 months ago

Heron Therapeutics Earnings Call Transcript: Q2 2025


Heron Therapeutics Quarterly report: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 10 months ago

Heron Therapeutics Quarterly report: Q2 2025


Heron Therapeutics Earnings release: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 10 months ago

Heron Therapeutics Earnings release: Q2 2025


Heron Therapeutics Slides: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 10 months ago

Heron Therapeutics Slides: Q2 2025


Heron Therapeutics reports Q2 EPS (2c), consensus (1c)

2025-08-08T11:52:19.000Z - 10 months ago

Heron Therapeutics reports Q2 EPS (2c), consensus (1c)


Heron Therapeutics Earnings Call Transcript: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q1 2025


Heron Therapeutics Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Earnings release: Q1 2025


Heron Therapeutics Quarterly report: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Quarterly report: Q1 2025


Heron Therapeutics Slides: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Slides: Q1 2025


Heron Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q4 2024


Heron Therapeutics Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Annual report: Q4 2024


Heron Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings release: Q4 2024


Heron Therapeutics Slides: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Slides: Q4 2024


U.S. District Court Upholds Validity of CINVANTI® Patents

Dec 3, 2024, 4:36 PM EST - 1 year ago

U.S. District Court Upholds Validity of CINVANTI® Patents


Heron Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q3 2024


Heron Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Quarterly report: Q3 2024


Heron Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings release: Q3 2024


Heron Therapeutics Slides: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Slides: Q3 2024


Heron Therapeutics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q2 2024


Heron Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Heron Therapeutics Quarterly report: Q2 2024


Heron Therapeutics Earnings release: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Heron Therapeutics Earnings release: Q2 2024


Heron Therapeutics Slides: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Heron Therapeutics Slides: Q2 2024


Heron Therapeutics Transcript: Investor Day 2024

May 15, 2024, 9:30 AM EDT - 2 years ago

Heron Therapeutics Transcript: Investor Day 2024


Heron Therapeutics Slides: FY 2024

May 15, 2024, 9:30 AM EDT - 2 years ago

Heron Therapeutics Slides: FY 2024


Heron Therapeutics Earnings Call Transcript: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q1 2024


Heron Therapeutics Quarterly report: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Quarterly report: Q1 2024


Heron Therapeutics Earnings release: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Earnings release: Q1 2024


Heron Therapeutics Slides: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Slides: Q1 2024


Heron Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics Proxy statement: Proxy Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics Earnings Call Transcript: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q4 2023


Heron Therapeutics Annual report: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Annual report: Q4 2023


Heron Therapeutics Earnings release: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Earnings release: Q4 2023


Heron Therapeutics Slides: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Slides: Q4 2023


Heron Therapeutics Earnings Call Transcript: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q3 2023


Heron Therapeutics Quarterly report: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Heron Therapeutics Quarterly report: Q3 2023


Heron Therapeutics Earnings release: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Heron Therapeutics Earnings release: Q3 2023


Heron Therapeutics Slides: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Heron Therapeutics Slides: Q3 2023


Heron Therapeutics Registration statement: Registration Filing

Aug 23, 2023, 8:00 AM EDT - 3 years ago

Heron Therapeutics Registration statement: Registration Filing


Heron Therapeutics Earnings Call Transcript: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Earnings Call Transcript: Q2 2023


Heron Therapeutics Quarterly report: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Quarterly report: Q2 2023


Heron Therapeutics Earnings release: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Earnings release: Q2 2023


Heron Therapeutics Slides: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Slides: Q2 2023


SpaceForceOne
SpaceForceOne Jun. 5 at 3:59 PM
$HRTX Brad- Neither is going to happen, if even for years to come. While steps to avoid such claims could / will be detrimental to current investors, I am confident $HRTX is NOT going to be delisted or bankrupt. The competitive generic Civ product wouldn’t be mass produced at the earliest until late sometime 2028 in perfect conditions. $HRTX stated they have cash on hand for short term. This stock will fluctuate I bet a few times between now and PFS. Tell everyone who has blocked me, I have proclaimed. lol.
2 · Reply
Braddog
Braddog Jun. 5 at 3:40 PM
$HRTX The shorts are going to force Heron into a bad situation! Someone doesn’t want Zyn in the market I wonder who that could be? 😡
0 · Reply
Ethan11111
Ethan11111 Jun. 5 at 3:26 PM
$HRTX the stock price is ridiculous, almost impossible...
1 · Reply
Braddog
Braddog Jun. 5 at 3:15 PM
$HRTX We could see the price in $0.20s.
0 · Reply
Braddog
Braddog Jun. 5 at 3:11 PM
$HRTX The shorts will not let up until Heron is de-listed or BK! The only way out of this is a structural change in the Company! Pray I get some of my $$$ back!
0 · Reply
BullMaven
BullMaven Jun. 5 at 2:30 PM
$HRTX keep adding
1 · Reply
Braddog
Braddog Jun. 5 at 1:52 PM
$HRTX Heron saying that Q1 sales were bad because of the weather is such a joke! I believe BQ once blamed poor sales on the weather! COLLARD HAS FAILED! His primary job is bring shareholder value! 😡 Where are the Blockbuster sales! 😡
1 · Reply
Braddog
Braddog Jun. 5 at 1:32 PM
$HRTX After this horrible week if your a long investor, HERON has several concerns 1st The loss against Azurity is worse than people think Its is setting us back years AGAIN if you are a long investor 2nd If Heron needs money to keep operation going, long investors most likely will be more Fucked! Not a lot of good outcomes 3rd Will Heron have to Reverse split? No way this goes above $1 without structural change or winning the Appeal! 4th. The shorts aren’t going anywhere! They finally got Heron pinned down and are going in for the kill! Seriously I think selling this for whatever is our only way out I can’t imagine Rubic and Velan want to hang around here for 5 more years Heron is cursed. Nothing goes its way Nothing. Collard hasn’t done his job! I’m still want to know the truth about Azurity’s argument because COLLARD AND TEAM said it was the SAME JUDGE with the SAME ARGUEMENT! Well it WASN’T! WISH I NEVER HEARD OF HERON!
0 · Reply
Alon_R
Alon_R Jun. 5 at 10:05 AM
$HRTX If Q2 once again reaffirms the $173–183M rev. guidance & $10–20M EBITDA, I believe SP could move well above $1 in a short period, possibly even $2+ range this year. The reasoning is straightforward-> First & foremost, the company is financially sound. That's the foundation. Second, we're seeing rapid uptake of two approved franchises. According to guidance, they are expected to grow ~80% YoY on average! Anyone who understands what strong adoption & rapid growth of two approved franchises can lead to knows where this is heading. More importantly, this growth validates the company's financial strength going forward. If both franchises generate ~$90M in 2026 after growing ~80%, the likely paths are either continued rapid expansion, becoming first-line treatments, or a moderation to ~40% growth. Either way,the company becomes financially solid & continue growing from there. And yes, in that scenario, it becomes an attractive buyout candidate, potentially $500–700M range.
2 · Reply
Suhada_95
Suhada_95 Jun. 5 at 4:31 AM
$HRTX My short selling friends, I hope you are still strong enough to lower the price of this stock to 0.35, because my average price is only at 0.79$
1 · Reply
davidtmc
davidtmc Jun. 5 at 1:09 AM
$HRTX personally, just not seeing anything that created this huge drop in SP other than a drastic overreact by all the well coordinated goons who were very successful in orchestrating a well planned sell-off
0 · Reply
Tacto
Tacto Jun. 4 at 11:21 PM
$HRTX They drained the standard shorting pool. There's nothing but a paltry 30k in there now. The bad guys will either have to keep selling abusive-naked shorts (counterfeits) into the float to delay their demise, if the primes will even allow that, or the goons will have to commence covering the many tens of millions of standard shorts and abusive-naked shorts, and where are they gonna find genuine shares to do this, when none of the biggies are selling, and the stock is primarily held by institutions, so going after retail ain't even gonna scratch the surface.. I'll keep loading until..... KABOOM!!! . .
2 · Reply
Tacto
Tacto Jun. 4 at 10:35 PM
$HRTX Stochastic Buy Signal today In the lower part of the picture you can see where the %K (blue) line crossed above the %D (red) in Oversold territory (<20%) . . .
0 · Reply
SpaceForceOne
SpaceForceOne Jun. 4 at 7:55 PM
$HRTX Seems like you wrote a lot of words which means nothing to anyone in terms of the original question. Ridiculous . Why didn’t you just say you simply don’t know when or how much $HRTX added last to the ESPP?
1 · Reply
ITrustno1
ITrustno1 Jun. 4 at 7:54 PM
$HRTX fine… $89M MC! BS!! Avg’d down: cost basis @0.63 feels good for a summer fling 😎 Though, man …my buy hit zero resistance, someone is selling hard and fast! Next Earnings expected to be better than last, and even if it was the same I believe this will be over $1… well over that IMO gambling mood. Cheap bet down here, and can afford the risk. Bullish from this SP at least.
0 · Reply
Alon_R
Alon_R Jun. 4 at 7:22 PM
$HRTX Heron is expected to generate ~ $10–20M in positive Adjusted EBITDA this year. Let it sink in-> That’s exceptionally good! Many companies with Market Cap, fivefold higher than Heron's still losing a lot of money and do not generate positive Adjusted EBITDA, or are nowhere close to doing so! But Heron is already there. It is already on the verge of profitability, and its current MC seems disconnected from that reality. Even in a worst-case scenario, it is difficult to justify a valuation anywhere near the current Market Cap, given its two rapidly growing franchises, ZYNRELEF & APONVIE, and whatever contribution CINVANTI may provide going forward. Even if the company only had ZYNRELEF & APONVIE, which are expected to grow by ~ 80% this year, that alone could support a much higher valuation before taking any CINVANTI revenue into account. I don't recognize similar strong upside opportunity in that spectrum... as current Market Cap is as failed clinical-stage company.
1 · Reply
Braddog
Braddog Jun. 4 at 6:59 PM
$HRTX Here is a good organization trying to help people make Non-opioid choices! But honestly, the whole process is a joke! The way the FDA gave HTX-011 fast track, etc….. What a fuking Joke! Got a bigger better opioid you need approved, done approved! Got an opiod alternative that needs approval, let’s turn it down twice and give it a skinny label. The entire system is a Fing Joke! A Fing Joke! Why even bother trying to bring anything to market. And the shorts have been at Heron for years. Something doesn’t smell right
0 · Reply
SpaceForceOne
SpaceForceOne Jun. 4 at 6:39 PM
$HRTX $HRTX Can you tell me the last time , and how many shares $HRTX increased the number of shares because there was insufficient shares for that organizational program? I can, here’s a hint. Don’t look too far back. So to your point, was that increase bullish? Is the company and SP stringer today?
2 · Reply
Alon_R
Alon_R Jun. 4 at 6:21 PM
$HRTX Personally, I view the addition of 10M(optional) shares to the Employee Stock Purchase Plan, for the years to come, as a bullish sign. Because it suggests the following-> our franchises are growing very well (with ZYNRELEF and APONVIE expected to grow by around 80% in 2026), we are seeing strong demand going forward, and we want to maintain that rapid uptake in 2027 and 2028. Therefore, these shares will be available to support and incentivize employees as the franchises continue to expand and grow rapidly.
1 · Reply
Maissessap
Maissessap Jun. 4 at 6:20 PM
$HRTX Billions and trillions of shares, a never ending dilution ....
1 · Reply
Alon_R
Alon_R Jun. 4 at 6:09 PM
$HRTX Some more data-> Shareholders will vote on adding 16.56M shares to the 2007 Equity Incentive Plan (that will be in use along the years only if necessary) Adding 10M shares to the Employee Stock Purchase Plan (that will be used along the years). One important distinction-> this is not the same as issuing 26M new shares immediately into the market. Rather, it would increase the pool of shares available for future stock options, restricted stock units, and employee stock purchases. The actual dilution, if approved, would occur gradually and just if needed, as those shares are granted and vest over time.
0 · Reply
SpaceForceOne
SpaceForceOne Jun. 4 at 5:54 PM
$HRTX So the vote in 4 days to dilute by 26.5+ million shares goes less than 1/2 as far as they originally thought at this price.
0 · Reply